irinotecan

P2, N=50, Completed, Massachusetts General Hospital | Unknown status --> Completed

For OS, both cetuximab + chemotherapy [hazard ratio (HR)=0.853; 95% CI: 0.775-0.938; P=0.001] and panitumumab + chemotherapy (HR=0.855; 95% CI: 0.738-0.992; P=0.038) exhibited statistically significant superiority compared with bevacizumab + chemotherapy...In the present sensitivity analysis, UDP glucuronosyltransferase family 1 member A1-guided bevacizumab + 5-fluorouracil, leucovorin and irinotecan demonstrated favorable outcomes, with OS and PFS P-scores of 0.932 and 0.992, respectively; however, these findings were derived from a single trial with limited comparability...Treatment benefit from anti-EGFR therapy was markedly influenced by primary tumor location, with notable benefit observed in left-sided tumors and no benefit in right-sided tumors. These findings support tumor sidedness-guided treatment selection in clinical practice, favoring anti-EGFR-based therapy for left-sided and bevacizumab-based therapy for right-sided RAS wild-type mCRC.

P1, N=120, Not yet recruiting, Shanghai EpimAb Biotherapeutics Co., Ltd.

Plasma samples were obtained from patients with locally advanced and borderline resectable PDAC at baseline and following neoadjuvant chemotherapy, either FOLFIRINOX (5-FU [fluorouracil], leucovorin, oxaliplatin, and irinotecan) or GEM-ABRAX ( gemcitabine plus nab-paclitaxel), followed by stereotactic body radiation therapy (SBRT). Notably, the expression profiles of these miRNAs demonstrated interpatient variability, though a subset of miRNAs showed statistically significant changes following treatment. These findings support the feasibility of sEV isolation and molecular profiling from patient plasma and warrant further investigation as a potential source of biomarkers in pancreatic cancer.

In non-metastatic disease, neoadjuvant treatment with modern chemotherapeutic regimens followed by surgical resection and/or adjuvant mFOLFIRINOX has significantly improved oncological outcomes...With a longer perspective, we explore how harnessing SC MO, SPT, AI, and systems biology can reveal the 3D spatial organization of interacting cancer, immune, and stromal cells. Multi-dimensional TME-, TSO500- and ctDNA-based framework of dynamic biomarkers are of paramount importance to achieve an optimal patient-specific perioperative multimodal treatment combining precision immunotherapy, targeted drugs, and modern chemotherapy, translated into future practice-changing clinical trials, that could eliminate MRD towards recurrence prevention.

P3, N=195, Recruiting, InnoPharmax Inc. | Not yet recruiting --> Recruiting

P2, N=81, Completed, Agenus Inc. | Active, not recruiting --> Completed

P1/2, N=128, Completed, Akeso | Trial completion date: Mar 2024 --> May 2026 | Trial primary completion date: Mar 2023 --> May 2026 | Recruiting --> Completed

The phase II RAMIRIS trial compared RAM plus paclitaxel with RAM plus FOLFIRI (5-fluororuracil, leucovorin and irinotecan) in this setting...Elevated PlGF-particularly its early increase during RAM-based therapy-was associated with shortened survival and may represent a dynamic marker of unfavorable prognosis in advanced gastric/GEJ adenocarcinoma. Given the exploratory nature of this analysis, these findings should be considered hypothesis-generating and require validation in independent biomarker-driven studies.

In UGT1A1*28 homozygous carriers, genotype-driven dosing reduced toxicity (21.1% vs. 45.7%, p = 0.086) while preserving comparable RDI (58% [IQR 50-69] vs. 61% [IQR 41-76], p = 0.906). These findings suggest uniform genotype-based strategies may not fully capture variant-specific effects, particularly for DPYD c.1236G>A (HapB3), supporting more flexible dosing approaches.

P2/3, N=35, Not yet recruiting, Astellas Pharma Global Development Inc.

P1, N=448, Recruiting, Alterome Therapeutics, Inc. | N=188 --> 448